Docebo (DCBO) Q3 2026 Earnings Call Transcript

Docebo reported Q3 2026 revenue of $70.3 million, up 14% year over year, and raised full-year revenue guidance to $276.7 million, implying about 14% growth versus its initial 10.6% target. Adjusted net income rose to $14.0 million from $9.9 million, while ARR increased 11% to $261.5 million and average contract value rose 24% to $77,900. The company declared a one-time $60 million special dividend ($2.42 per share), funded by increasing debt capacity to $150 million; management cited a 1.9x net-debt-to-adjusted-EBITDA ratio. FX pressure, delayed government deals, and a higher professional-services mix weighed on near-term outlook or margins, while management cited more than 600 beta customers for new AI-driven products.

Analysis

Investment view: The key question is whether higher contract values translate into durable ARR acceleration—not simply larger deals with longer sales cycles. Enterprise mix and multi-product adoption can lift ACV while concentrating execution risk in fewer procurement-heavy wins. Government deal slippage into Q4 and healthcare ramp costs make the next 1–3 months a conversion test; pipeline commentary is not booked revenue. The 600-plus AI beta cohort is evidence of product engagement, not yet evidence of paid attach or retention uplift.

Competitive dynamics: Knowledge and skills features could broaden Docebo’s buyer set beyond L&D, but connectors to SharePoint, Salesforce and other enterprise repositories make those systems complements as much as competitors. CIO security, governance and implementation reviews could lengthen sales cycles even as the addressable budget expands. Legacy LMS vendors may face more displacement pressure if Docebo demonstrates credible enterprise-scale deployment and cross-sell.

Risk / contrarian: Debt-funded capital returns alongside softer quarterly free-cash-flow conversion reduce flexibility if enterprise bookings slip or vertical investments take longer to pay back. Conversely, the market may underweight the potential for product breadth to increase expansion revenue; the company has not yet quantified attach rates or AI monetization. The dividend is a capital-allocation choice, not proof of accelerating cash generation. Over 6–18 months, the thesis depends on recurring subscription growth and margin recovery as services mix normalizes.

Falsifiers: weaker ARR growth, continued deterioration in cash conversion, leverage rising above management’s stated level, or delayed large deals without subsequent bookings conversion would undermine the constructive case.

Key Decisions for Investors

• Avoid chasing the capital-return headline. Treat DCBO as a conditional long/watch: consider initiating only after the next results confirm enterprise pipeline conversion into ARR and provide a credible 2027 outlook; no valuation data here supports a price target.
• For the February results, track ARR growth, subscription gross margin, free-cash-flow conversion, and paid adoption/attach rates for Knowledge, skills and AI products. A beta count without monetization or retention evidence is not a catalyst by itself.
• Reassess or exit a constructive thesis if ARR growth materially decelerates, major government/enterprise deals slip again without conversion, cash conversion weakens further, or net leverage moves above the reported 1.9x without a clear investment payoff.